Cart
0
Get 20% Free Customization In This Report
Buy this report from - $4176

Immunoglobulin Market by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre syndrome, and Others), Product Type (IgG, IgA, IgM, IgE, and IgD), and by Mode of Delivery (Intravenous [5%, 10%, and Other Concentrations] and Subcutaneous [16.5%, 20%, and Other Concentrations]) - Global Opportunity Analysis and Industry Forecast, 2017-2023

LI_172586
Pages: 220
Jul 2017 | 1808 Views
face gplus_n
Author's : Onkar Sumant and Tenzin Kunsel
Tables: 133
Charts: 11
twit_n pr_n

Immunoglobulin Market Overview:

Global Immunoglobulin Market was valued at $8,374 million in 2016, and is projected to reach $13,619 million by 2023, registering a CAGR of 7.3% from 2017 to 2023. Immunoglobulin is a protein produced by plasma cells and other lymphocytes. They are highly complex entities that exert their immunomodulatory effect on the different components of the immune system. They are obtained from blood by fractionation process and purified for therapeutic and non-therapeutic applications. Different classes of immunoglobulin such as IgG, IgA, and IgM are used for the treatment of various immunological and neurological diseases. These immunoglobulins can be administered intravenously and subcutaneously.

The report segments the global immunoglobulin market based on application, product type, mode of delivery, and concentration. Applications covered in the study include hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, GBS, and others. Based on product type, the market is segmented into immunoglobulin G (IgG), IgA, IgM, IgE, and IgD. By mode of delivery, it is bifurcated into intravenous and subcutaneous. Intravenous mode of delivery is further categorized into 5%, 10%, and other concentration. Subcutaneous mode of delivery is further classified into 16.5%, 20%, and other concentration.

The market is expected to witness a moderate growth during the forecast period, owing to Increase in geriatric population & number of hemophilic patients, improved immunoglobulin production owing to the emergence of advanced technologies, and enhanced purification techniques (with better plasma yield). Furthermore, surge in prevalence of chronic inflammatory demyelinating polyneuropathy (CIDP) & hypogammaglobulinemia and rise in use of immunoglobulins to treat Guillain-Barre syndrome (GBS), inflammatory myopathies, specific antibody deficiency, and others, are expected to boost the market growth. However, stringent government regulations toward immunoglobulin products, expensive therapy, and high risk of side effects associated with the use of immunoglobulin are expected to hamper this market growth.

The report provides extensive competitive analysis and profiles of key market players that includes Baxter international Inc., CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products, Inc., BDI Pharma Inc., and Bayer Healthcare.

Other players in the value chain include Hualan Biological Engineering Inc., Omrix Biopharmaceuticals Ltd., Behring GmbH, Shanghai RAAS Blood Products Co., Ltd., Option Care Enterprises, Inc., ADMA Biologics, Inc., and BioScrip, Inc.

North America is the largest contributor toward the global market, followed by Asia-Pacific. These regions collectively occupy almost 75% of the global market revenue. Presence of the largest plasma production facilities and high adoption rate in the developed countries majorly boost the market growth.

India immunoglobulin market is projected to grow at a CAGR of 8.1% during the forecast period.

Key Benefits

  • This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
  • Market estimations are based on comprehensive analysis of the key developments in the industry.
  • The global market is comprehensively analyzed with respect to products type, application, mode of delivery, and geography.
  • In-depth analysis based on geography assists in understanding the regional market to assist in strategic business planning.
  • The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

Immunoglobulin Market Key Segments:

By Application

  • Hypogammaglobulinemia
  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • Immunodeficiency Diseases
  • Myasthenia Gravis
  • Multifocal Motor Neuropathy
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Inflammatory Myopathies
  • Specific Antibody Deficiency
  • Guillain-Barr Syndrome
  • Others

By Product

  • IgG
  • IgA
  • IgM
  • IgE
  • IgD

By Mode of Delivery

  • Intravenous
    • 5% Concentration
    • 10% Concentration
    • Others
  • Subcutaneous
    • 16.5% Concentration
    • 20% Concentration
    • Others

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Austria
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Turkey
    • Argentina
    • Saudi Arabia
    • Rest of LAMEA
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. OVERVIEW OF IMMUNOGLOBULIN

3.2.1. Patented products

3.3. EPIDEMIOLOGY AND ECONOMIC BURDEN OF CHRONIC CONDITIONS
3.4. COST OF SIDE EFFECTS OF IMMUNOGLOBULIN TREATMENT
3.5. KEY FINDINGS

3.5.1. Top factors impacting
3.5.2. Top investment pockets

3.6. PORTER’S FIVE FORCES ANALYSIS
3.7. VALUE CHAIN ANALYSIS

3.7.1. Primary activities
3.7.2. Support activities

3.8. MARKET SHARE ANALYSIS, 2016
3.9. PRODUCT SCENARIO IN IMMUNOGLOBULIN MARKET
3.10. GOVERNMENT REGULATIONS AND REIMBURSEMENTS

3.10.1. U.S.
3.10.2. Europe

3.10.2.1. France
3.10.2.2. Germany
3.10.2.3. Italy

3.10.3. China
3.10.4. Japan
3.10.5. India

3.11. INDICATIONS FOR IMMUNOGLOBULIN

3.11.1. U.S. FDA indications
3.11.2. EMA

3.12. COMPONENT ANALYSIS OF IMMUNOGLOBULIN G (IGG)

3.12.1. IgG1
3.12.2. IgG2
3.12.3. IgG3
3.12.4. IgG4

3.13. CLINICAL TRIALS
3.14. MARKET DYNAMICS

3.14.1. Drivers

3.14.1.1. Rise in prevalence of immunodeficiency diseases
3.14.1.2. Increase in adoption of immunoglobulin
3.14.1.3. Increase in incidence of bleeding disorders
3.14.1.4. Surge in geriatric population

3.14.2. Restraints

3.14.2.1. Stringent government regulations
3.14.2.2. High cost of therapy

3.14.3. Opportunities

3.14.3.1. Opportunities in emerging economies
3.14.3.2. Development of cost-effective therapeutics through large-scale production

Chapter: 4 IMMUNOGLOBULIN MARKET, BY APPLICATION

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. HYPOGAMMAGLOBULINEMIA

4.2.1. Market size and forecast

4.3. CIDP

4.3.1. Market size and forecast

4.4. PRIMARY IMMUNODEFICIENCY DISEASES

4.4.1. Market size and forecast

4.5. MYASTHENIA GRAVIS

4.5.1. Market size and forecast

4.6. MULTIFOCAL MOTOR NEUROPATHY

4.6.1. Market size and forecast

4.7. PRIMARY ITP

4.7.1. Market size and forecast

4.8. INFLAMMATORY MYOPATHIES

4.8.1. Market size and forecast

4.9. SAD

4.9.1. Market size and forecast

4.10. GBS

4.10.1. Market size and forecast

4.11. OTHERS

4.11.1. Market size and forecast

Chapter: 5 IMMUNOGLOBULIN MARKET, BY PRODUCT

5.1. OVERVIEW
5.2. IGG

5.2.1. Key market trends
5.2.2. Clinical interpretations

5.3. IGA

5.3.1. Key market trends
5.3.2. Clinical interpretation

5.4. IGM

5.4.1. Key market trends
5.4.2. Clinical interpretation

5.5. IGE

5.5.1. Key market trends
5.5.2. Clinical Interpretation

5.6. IMMUNOGLOBULIN D (IGD)

5.6.1. Key market trends
5.6.2. Clinical interpretations

Chapter: 6 IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. INTRAVENOUS MODE OF DELIVERY

6.2.1. Key market trends
6.2.2. Market size and forecast
6.2.3. 5% concentration

6.2.3.1. Market size and forecast

6.2.4. 10% concentration

6.2.4.1. Market size and forecast

6.2.5. Other concentrations

6.2.5.1. Market size and forecast

6.3. SUBCUTANEOUS MODE OF DELIVERY

6.3.1. Key market trends
6.3.2. Market size and forecast
6.3.3. 16.5% concentration

6.3.3.1. Market size and forecast

6.3.4. 20% concentration

6.3.4.1. Market size and forecast

6.3.5. Other concentrations

6.3.5.1. Market size and forecast

Chapter: 7 IMMUNOGLOBULIN MARKET, BY GEOGRAPHY

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Market size and forecast
7.2.3. North America IVIG market

7.2.3.1. Market size and forecast

7.2.4. North America SCIG market

7.2.4.1. Market size and forecast

7.2.5. U.S.

7.2.5.1. Market size and forecast
7.2.5.2. U.S. IVIG market size and forecast
7.2.5.3. U.S. SCIG market size and forecast

7.2.6. Canada

7.2.6.1. Market size and forecast
7.2.6.2. Canada IVIG market size and forecast
7.2.6.3. Canada SCIG market size and forecast

7.2.7. Mexico

7.2.7.1. Market size and forecast
7.2.7.2. Mexico IVIG market size and forecast
7.2.7.3. Mexico SCIG market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Market size and forecast
7.3.3. Europe IVIG market

7.3.3.1. Market size and forecast

7.3.4. Europe SCIG market

7.3.4.1. Market size and forecast

7.3.5. UK

7.3.5.1. Market size and forecast
7.3.5.2. UK IVIG market size and forecast
7.3.5.3. UK SCIG market size and forecast

7.3.6. France

7.3.6.1. Market size and forecast
7.3.6.2. France IVIG market size and forecast
7.3.6.3. France SCIG market size and forecast

7.3.7. Germany

7.3.7.1. Market size and forecast
7.3.7.2. Germany IVIG market size and forecast
7.3.7.3. Germany SCIG market size and forecast

7.3.8. Italy

7.3.8.1. Market size and forecast
7.3.8.2. Italy IVIG market size and forecast
7.3.8.3. Italy SCIG market size and forecast

7.3.9. Austria

7.3.9.1. Market size and forecast
7.3.9.2. Austria IVIG market size and forecast
7.3.9.3. Austria SCIG market size and forecast

7.3.10. Russia

7.3.10.1. Market size and forecast
7.3.10.2. Russia IVIG market size and forecast
7.3.10.3. Russia SCIG market size and forecast

7.3.11. Rest of Europe

7.3.11.1. Market size and forecast
7.3.11.2. Rest of Europe IVIG market size and forecast
7.3.11.3. Rest of Europe SCIG market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Market size and forecast
7.4.3. Asia-Pacific IVIG market

7.4.3.1. Market size and forecast

7.4.4. Asia-Pacific SCIG market

7.4.4.1. Market size and forecast

7.4.5. Australia

7.4.5.1. Market size and forecast
7.4.5.2. Australia IVIG market size and forecast
7.4.5.3. Australia SCIG market size and forecast

7.4.6. China

7.4.6.1. Market size and forecast
7.4.6.2. China IVIG market size and forecast
7.4.6.3. China SCIG market size and forecast

7.4.7. Japan

7.4.7.1. Market size and forecast
7.4.7.2. Japan IVIG market size and forecast
7.4.7.3. Japan SCIG market size and forecast

7.4.8. India

7.4.8.1. Market size and forecast
7.4.8.2. India IVIG market size and forecast
7.4.8.3. India SCIG market size and forecast

7.4.9. Rest of Asia-Pacific

7.4.9.1. Market size and forecast
7.4.9.2. Rest of Asia-Pacific IVIG market size and forecast
7.4.9.3. Rest of Asia-Pacific SCIG market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Market size and forecast
7.5.3. LAMEA IVIG market

7.5.3.1. Market size and forecast

7.5.4. LAMEA SCIG market

7.5.4.1. Market size and forecast

7.5.5. Brazil

7.5.5.1. Market size and forecast
7.5.5.2. Brazil IVIG market size and forecast
7.5.5.3. Brazil SCIG market size and forecast

7.5.6. Argentina

7.5.6.1. Market size and forecast
7.5.6.2. Argentina IVIG market size and forecast
7.5.6.3. Argentina SCIG market size and forecast

7.5.7. Turkey

7.5.7.1. Market size and forecast
7.5.7.2. Turkey IVIG market size and forecast
7.5.7.3. Turkey SCIG market size and forecast

7.5.8. Saudi Arabia

7.5.8.1. Market size and forecast
7.5.8.2. Saudi Arabia IVIG market size and forecast
7.5.8.3. Saudi Arabia SCIG market size and forecast

7.5.9. Rest of LAMEA

7.5.9.1. Market size and forecast
7.5.9.2. Rest of LAMEA IVIG market size and forecast
7.5.9.3. Rest of LAMEA SCIG market size and forecast

LIST OF TABLES

TABLE 1. COMMERCIALIZED IMMUNOGLOBULIN PRODUCTS
TABLE 2. BASELINE IMMUNOGLOBULIN YEARLY COSTS (2009)
TABLE 3. U.S. FDA INDICATIONS FOR IMMUNOGLOBULIN
TABLE 4. EMA-APPROVED INDICATIONS FOR IMMUNOGLOBULIN
TABLE 5. IGG SUBCLASS
TABLE 6. FREQUENCY (%) OF DECREASED IGG SUBCLASS CONCENTRATION IN ADULTS
TABLE 7. DISEASES ASSOCIATED WITH IGG SUBCLASS DEFICIENCY
TABLE 8. CLINICAL TRIALS FOR IMMUNOGLOBULIN (2015-2016)
TABLE 9. GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 10. GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, 2016-2023 (KILOGRAM)
TABLE 11. COMMON MEDICATION FOR THE HYPOGAMMAGLOBULINEMIA ASSOCIATED WITH RECURRENT BACTERIAL INFECTIONS
TABLE 12. GLOBAL IMMUNOGLOBULIN MARKET FOR HYPOGAMMAGLOBULINEMIA, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 13. GLOBAL IMMUNOGLOBULIN MARKET FOR CIDP, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 14. PRINCIPLE OF IMMUNOGLOBULIN THERAPY IN IMMUNODEFICIENCY
TABLE 15. GLOBAL IMMUNOGLOBULIN MARKET FOR PRIMARY IMMUNODEFICIENCY DISEASE, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 16. GLOBAL IMMUNOGLOBULIN MARKET FOR MYASTHENIA GRAVIS, 2016-2023  ($MILLION AND KILOGRAM)
TABLE 17. GLOBAL IMMUNOGLOBULIN MARKET FOR MMN, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 18. ITP TREATMENT OPTIONS
TABLE 19. GLOBAL IMMUNOGLOBULIN MARKET FOR PRIMARY ITP, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 20. GLOBAL IMMUNOGLOBULIN MARKET FOR INFLAMMATORY MYOPATHY, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 21. GLOBAL IMMUNOGLOBULIN MARKET FOR SAD, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 22. GLOBAL IMMUNOGLOBULIN MARKET FOR GBS, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 23. GLOBAL IMMUNOGLOBULIN MARKET FOR OTHERS, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 24. GLOBAL IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2016-2023 ($MILLION)
TABLE 25. GLOBAL IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, 2016-2023 (KILOGRAM)
TABLE 26. GLOBAL IMMUNOGLOBULIN MARKET FOR INTRAVENOUS MODE OF DELIVERY, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 27. GLOBAL IVIG MARKET FOR 5% CONCENTRATION, 2016-2023  ($MILLION AND KILOGRAM)
TABLE 28. GLOBAL IVIG MARKET FOR 10% CONCENTRATION, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 29. GLOBAL IVIG MARKET FOR OTHER CONCENTRATIONS, 2016-2023  ($MILLION AND KILOGRAM)
TABLE 30. GLOBAL SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 31. GLOBAL SCIG MARKET FOR 16.5% CONCENTRATION, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 32. GLOBAL SCIG MARKET FOR 20% CONCENTRATION, 2016-2023  ($MILLION AND KILOGRAM)
TABLE 33. GLOBAL SCIG MARKET FOR OTHER CONCENTRATIONS, 2016-2023  ($MILLION AND KILOGRAM)
TABLE 34. IMMUNOGLOBULIN MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 35. IMMUNOGLOBULIN MARKET, BY GEOGRAPHY, 2016-2023 (KILOGRAM)
TABLE 36. NORTH AMERICA IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION & KILOGRAM)
TABLE 37. NORTH AMERICA IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 38. NORTH AMERICA SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 39. U.S. IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 40. U.S. IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 41. U.S. SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 42. CANADA IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 43. CANADA IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 44. CANADA SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 45. MEXICO IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 46. MEXICO IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 47. MEXICO SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 48. EUROPE IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION & KILOGRAM)
TABLE 49. EUROPE IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 50. EUROPE SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 51. UK IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 52. UK IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 53. UK SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 54. FRANCE IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 55. FRANCE IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 56. FRANCE SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 57. GERMANY IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 58. GERMANY IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 59. GERMANY SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 60. ITALY IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 61. ITALY IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 62. ITALY SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 63. AUSTRIA IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 64. AUSTRIA IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 65. AUSTRIA SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 66. RUSSIA IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 67. RUSSIA IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 68. RUSSIA SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 69. REST OF EUROPE IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 70. REST OF EUROPE IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 71. REST OF EUROPE SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 72. ASIA-PACIFIC IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION & KILOGRAM)
TABLE 73. ASIA-PACIFIC IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 74. ASIA-PACIFIC SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 75. AUSTRALIA IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 76. AUSTRALIA IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 77. AUSTRALIA SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 78. CHINA IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 79. CHINA IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 80. CHINA SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 81. JAPAN IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 82. JAPAN IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 83. JAPAN SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 84. INDIA IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 85. INDIA IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 86. INDIA SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 87. REST OF ASIA-PACIFIC IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 88. REST OF ASIA-PACIFIC IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 89. REST OF ASIA-PACIFIC SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 90. LAMEA IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION & KILOGRAM)
TABLE 91. LAMEA IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 92. LAMEA SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 93. BRAZIL IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 94. BRAZIL IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 95. BRAZIL SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 96. ARGENTINA IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 97. ARGENTINA IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 98. ARGENTINA SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 99. TURKEY IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 100. TURKEY IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 101. TURKEY SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 102. SAUDI ARABIA IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 103. SAUDI ARABIA IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 104. SAUDI ARABIA SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 105. REST OF LAMEA IMMUNOGLOBULIN MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 106. REST OF LAMEA IVIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)
TABLE 107. REST OF LAMEA SCIG MARKET, 2016-2023 ($MILLION AND KILOGRAM)

LIST OF FIGURES

FIGURE 1. MARKET SEGMENTATION
FIGURE 2. PERCENTAGE SHARE OF COST ASSOCIATED WITH SIDE EFFECTS INDUCED  BY IMMUNOGLOBULIN THERAPY
FIGURE 3. TOP IMPACTING FACTORS, 2016-2023
FIGURE 4. TOP INVESTMENT POCKETS
FIGURE 5. BARGAINING POWER OF BUYERS
FIGURE 6. BARGAINING POWER OF SUPPLIERS
FIGURE 7. THREAT OF NEW ENTRANTS
FIGURE 8. THREAT OF SUBSTITUTION
FIGURE 9. COMPETITIVE RIVALRY
FIGURE 10. VALUE CHAIN ANALYSIS
FIGURE 11. MARKET SHARE ANALYSIS, 2016

 

The immunoglobulin products gained significant attention in the recent years due to their high efficacy in the treatment of immune diseases. Immunoglobulin is considered to be the most effective treatment for hypogammaglobulinemia, CIDP, and immunodeficiency diseases. Hypogammaglobulinemia, CIDP, and immunodeficiency disorders are the largest immunoglobulin consuming indications in the global immunoglobulin market, owing to the large patient population and unavailability of effective alternative treatments.

Limited number of plasma donors hampers the market growth. To resolve this issue, immunoglobulin producers have appealed to the local government for favorable pricing policy in selective regions of the market and they have successfully gained support from government authorities. Therefore, the average price of immunoglobulin is projected to remain relatively stable during the forecast period.

Moreover, the substantial development in technology involved in plasma production and purification is expected to significantly increase the immunoglobulin production. In addition, the key players have decided to strengthen their research activities for the development of therapies for rare diseases through immunoglobulin products, which are anticipated to provide growth opportunities in the immunoglobulin market.

The administration of immunoglobulin is the highest in North America, owing to the increase in adoption of immunoglobulin products, high awareness regarding the benefits of using immunoglobulin therapies among the healthcare providers, and increase in disposable income among patients. Although the use of immunoglobulin in LAMEA is low, the adoption rate is expected to increase due to rise in disposable income, increase in healthcare expenditure, and government initiative to enhance the healthcare departments contribute toward market growth.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Request sample

OR

Purchase Full Report of
Immunoglobulin Market- Global Opportunity Analysis and Industry Forecast, 2017-2023

  • Online Only
  • $4176
  • Online cloud Access only
  • Restected Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $4640
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5540
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6654
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprice
    License/PDF

  • $9280
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  • Free quartery industry update
  • Free report update (Within 180 days)
  • Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo